Embedded Living HER2+ Cells in a 3D Gelatin–Alginate Hydrogel as an In Vitro Model for Immunotherapy Delivery for Breast Cancer

Embedded Living HER2+ Cells in a 3D Gelatin–Alginate Hydrogel as an In Vitro Model for Immunotherapy Delivery for Breast Cancer

Epidermal growth factor receptor 2 (HER2) is the second target molecule most commonly used in breast cancer treatment. Both recurrence and metastasis are still deadly for HER2+ breast cancer patients. Hydrogels can be an option for developing three-dimensional (3D) cell culture systems that resemble...

Full description

Bibliographic Details
Main Authors:	G. Tonantzin De Dios-Figueroa, Janette del Rocío Aguilera-Márquez, Lorena García-Uriostegui, Rodolfo Hernández-Gutiérrez, Tanya A. Camacho-Villegas, Pavel H. Lugo-Fabres
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Polymers
Subjects:	hydrogel three-dimensional (3D) cell culture living embedded cells breast cancer HER2+
Online Access:	https://www.mdpi.com/2073-4360/15/18/3726

Similar Items

3D Cell Culture Models in COVID-19 Times: A Review of 3D Technologies to Understand and Accelerate Therapeutic Drug Discovery
by: Guadalupe Tonantzin de Dios-Figueroa, et al.
Published: (2021-05-01)

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma
by: Giovanni Almadori, et al.
Published: (2021-09-01)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
by: Ezgi Tulukcuoglu Guneri, et al.
Published: (2022-04-01)

Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer
by: Paolo D’Amico, et al.
Published: (2021-12-01)

A Review on the Adaption of Alginate-Gelatin Hydrogels for 3D Cultures and Bioprinting
by: Magdalena B. Łabowska, et al.
Published: (2021-02-01)

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
by: Costa R, et al.
Published: (2019-01-01)

HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration
by: Di Yang, et al.
Published: (2023-10-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Delivery of Mesenchymal Stem Cells from Gelatin–Alginate Hydrogels to Stomach Lumen for Treatment of Gastroparesis
by: Binata Joddar, et al.
Published: (2018-02-01)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
by: Andres Lopez-Albaitero, et al.
Published: (2017-03-01)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
by: Diana B. Peckys, et al.
Published: (2021-11-01)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
by: Yanjie Han, et al.
Published: (2023-04-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
by: Serenella M. Pupa, et al.
Published: (2021-09-01)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
by: Sven Roßwag, et al.
Published: (2021-04-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Ultrasensitive assay of HER1, HER2, and heregulin-α in whole blood
by: Raluca-Ioana Stefan-van Staden, et al.
Published: (2022-12-01)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
by: Jeroen Claus, et al.
Published: (2018-05-01)

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
by: Doo-Yi Oh, et al.
Published: (2017-08-01)

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors
by: Kenny Chitcholtan, et al.
Published: (2020-03-01)

Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
by: Nischal Koirala, et al.
Published: (2022-06-01)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging
by: Brooke N. McKnight, et al.
Published: (2018-10-01)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
by: Tejaswini P. Reddy, et al.
Published: (2020-05-01)

Generation of CHO Stable Cell Line Overexpressing HER2: an In Vitro Model for Breast Cancer
by: Akbar Hedayatizadeh-Omran, et al.
Published: (2015-07-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
by: Lena-Christin Conradi, et al.
Published: (2019-09-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
by: Lisandra Negrón-Vega, et al.
Published: (2022-09-01)

Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
by: Esmaeil Dorraji, et al.
Published: (2022-10-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

Investigation of HER-2 expression and its Correlation with clinicopathological parameters and overall survival of esophageal squamous cell carcinoma patients
by: Mitra Heidarpour, et al.
Published: (2020-10-01)

Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy
by: Milena Perrone, et al.
Published: (2021-12-01)

The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells
by: Li-Fei Sun, et al.
Published: (2020-08-01)

Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
by: Peng Zhang, et al.
Published: (2018-10-01)